纳武利尤单抗联合伊匹木单抗对比纳武利尤单抗或化疗在MSI-H/dMMR转移性结直肠癌中的最终结果:CheckMate 8HW
CheckMate 8HW III期试验达到双重主要终点,NIVO+IPI较化疗(一线)和NIVO(全线)显著改善PFS。最终OS分析显示,NIVO+IPI较NIVO全线显著OS获益(HR 0.61,95%CI 0.46-0.82,P=0.0009),较化疗一线显著OS获益(HR 0.37,95%CI 0.24-0.57,P<0.0001)。一线NIVO+IPI较NIVO的OS获益具有临床意义(HR 0.66,95%CI 0.44-0.99,P=0.0432),但未达预设显著性阈值(P<0.006)。
要点
- NIVO+IPI较NIVO全线显著改善OS,HR 0.61。
- NIVO+IPI一线较化疗显著改善OS,HR 0.37。
- 一线NIVO+IPI较NIVO的OS获益未达预设显著性阈值。
核心结论
- NIVO+IPI较NIVO全线及较化疗一线均显示显著OS获益,支持其作为MSI-H/dMMR mCRC的标准治疗。
研究设计与样本
- III期CheckMate 8HW试验,839例免疫治疗初治的MSI-H/dMMR mCRC患者随机2:2:1分配至NIVO+IPI、NIVO或化疗±靶向治疗。
- 疗效分析在中心确认的MSI-H/dMMR人群中进行,全线和治疗组中位随访68.0个月(范围37.6-81.4个月)。
主要发现
- NIVO+IPI较NIVO全线OS HR 0.61(95%CI 0.46-0.82,P=0.0009)。
- NIVO+IPI一线较化疗OS HR 0.37(95%CI 0.24-0.57,P<0.0001)。
- 一线NIVO+IPI较NIVO OS HR 0.66(95%CI 0.44-0.99,P=0.0432),未达预设显著性阈值P<0.006。
- PFS在三个比较中均支持NIVO+IPI:全线较NIVO HR 0.60,一线较化疗HR 0.21,一线较NIVO HR 0.68。
- NIVO+IPI组3/4级治疗相关不良事件发生78例(22%),NIVO组50例(14%),无新的安全性问题或额外治疗相关死亡。
关键数值与推荐
- NIVO+IPI方案:NIVO 240 mg联合IPI 1 mg/kg每3周一次共4次,后NIVO 480 mg每4周一次。
- NIVO方案:NIVO 240 mg每2周一次共6次,后480 mg每4周一次。
- 化疗±靶向治疗为对照。
临床怎么用
- NIVO+IPI可作为MSI-H/dMMR mCRC的全线标准治疗,尤其一线较化疗显著改善OS。
- 一线NIVO+IPI较NIVO的OS获益具有临床意义但未达预设显著性阈值,需结合PFS等综合决策。
局限性
- 一线NIVO+IPI较NIVO的OS比较未达预设显著性阈值(P<0.006)。
- 3/4级治疗相关不良事件在NIVO+IPI组发生率高于NIVO组(22% vs 14%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The phase III CheckMate 8HW trial met its dual primary endpoints of superior progression-free survival (PFS) with nivolumab plus ipilimumab (NIVO + IPI) versus chemotherapy [first-line (1L)] and versus NIVO (all lines) in patients with centrally confirmed microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC). We report prespecified final overall survival (OS) analyses and updated efficacy outcomes. PATIENTS AND METHODS: Immunotherapy-naïve adults with mCRC across different lines and MSI-H/dMMR by local testing were randomly assigned 2 : 2 : 1 to NIVO (240 mg) plus IPI (1 mg/kg) once every 3 weeks for four doses and then NIVO 480 mg once every 4 weeks; NIVO (240 mg) once every 2 weeks (six doses) and then 480 mg once every 4 weeks; or chemotherapy ± targeted therapies. Secondary endpoints include PFS in NIVO + IPI versus NIVO (1L) and OS and objective response rate in the centrally confirmed MSI-H/dMMR population. RESULTS: In total, 839 patients across all lines were randomly assigned; efficacy analyses were conducted in those with centrally confirmed MSI-H/dMMR. Median follow-up across all lines and treatment groups was 68.0 months (range 37.6-81.4 months). NIVO + IPI demonstrated significant OS benefit compared with NIVO across all lines [hazard ratio (HR) 0.61, 95% confidence interval (CI) 0.46-0.82, P = 0.0009] and with chemotherapy in 1L (HR 0.37, 95% CI 0.24-0.57, P < 0.0001). Clinically meaningful OS benefit was noted with 1L NIVO + IPI versus NIVO (HR 0.66, 95% CI 0.44-0.99, P = 0.0432), not meeting the prespecified threshold for significance (P < 0.006). PFS continued to favor NIVO + IPI across all three comparisons: NIVO (all lines; HR 0.60), chemotherapy (1L; HR 0.21), and NIVO (1L; HR 0.68). Grade 3/4 treatment-related adverse events occurred in 78 (22%) versus 50 (14%) patients treated with NIVO + IPI versus NIVO across all lines, with no new safety concerns or additional treatment-related deaths from the previous follow-up. CONCLUSIONS: NIVO + IPI showed significant OS benefit compared with NIVO across all lines and with chemotherapy in 1L, while providing a clinical OS benefit versus NIVO in 1L, reinforcing its standard-of-care status in MSI-H/dMMR mCRC.
引用
- Lonardi S, Lenz HJ, Elez E, et al. Final results of nivolumab plus ipilimumab versus nivolumab or chemotherapy in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW. Ann Oncol. 2026. PMID: 42926106. doi:10.1016/j.annonc.2026.09.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。